Sysmex Corporation

TSE:6869 Rapport sur les actions

Capitalisation boursière : JP¥1.2t

Sysmex Croissance future

Future contrôle des critères 2/6

Sysmex devrait augmenter ses bénéfices et son chiffre d'affaires de 12.9% et de 5.1% par an respectivement. Le BPA devrait croître de de 13.4% par an. Le rendement des capitaux propres devrait être 10.6% dans 3 ans.

Informations clés

12.9%

Taux de croissance des bénéfices

13.36%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices9.6%
Taux de croissance des recettes5.1%
Rendement futur des capitaux propres10.60%
Couverture par les analystes

Good

Dernière mise à jour18 Aug 2026

Mises à jour récentes de la croissance future

Article d’analyse • May 17

Sysmex Corporation (TSE:6869) Annual Results: Here's What Analysts Are Forecasting For This Year

Last week saw the newest yearly earnings release from Sysmex Corporation ( TSE:6869 ), an important milestone in the...
Article d’analyse • Feb 15

Sysmex Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

There's been a notable change in appetite for Sysmex Corporation ( TSE:6869 ) shares in the week since its quarterly...

Recent updates

Mise à jour du récit • Aug 15

6869: Earnings Upgrade And Buyback Will Support A Steady Outlook

Analysts have lifted their price target on Sysmex to ¥1,800 from ¥1,732.67, citing updated assumptions around slightly higher profit margins and a lower projected future P/E multiple that together reshape their valuation view. What’s in the News for Sysmex Sysmex raised consolidated earnings guidance for the six months ending September 30, 2026, now projecting net sales of ¥265,000 million, operating profit of ¥25,000 million and profit attributable to owners of the parent of ¥15,000 million or ¥24.68 per basic share, compared with previous guidance of net sales of ¥255,000 million, operating profit of ¥23,000 million and profit attributable to owners of the parent of ¥14,000 million or ¥22.53 per basic share.
Mise à jour du récit • Aug 01

6869: Share Buybacks And New Collaboration Will Support Stronger Returns

Analysts have raised their price target on Sysmex from ¥2,655 to ¥2,747, citing updated assumptions for revenue growth, profit margins, and a slightly lower discount rate that influence their valuation and P/E expectations. What’s in the News for Sysmex Sysmex completed a share buyback program announced on March 5, 2026, repurchasing a total of 21,138,200 shares, representing 3.41% of shares, for ¥29,999.88 million as of July 17, 2026.
Nouveau récit • Jun 21

Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings

Catalysts About Sysmex Sysmex is a global diagnostics company focused on hematology, hemostasis, urinalysis and related testing systems for clinical laboratories and hospitals. What are the underlying business or industry changes driving this perspective?
Article d’analyse • Jun 17

Sysmex (TSE:6869) Stock Could Be 17.8% Undervalued After VolitionRx Collaboration

Collaboration news puts Sysmex stock in focus Sysmex (TSE:6869) is back on investors' radar after VolitionRx Limited announced a collaboration to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform, targeting diseases linked to NETosis. See our latest analysis for Sysmex. At a share price of ¥1,424.5, Sysmex has seen modest positive share price momentum in the past month with a 1-month share price return of 3.11% and 90-day share price return of 2.85%, yet the 1-year total shareholder...
Nouveau récit • Jun 07

Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects

Catalysts About Sysmex Sysmex is a diagnostics company focused on hematology, hemostasis, urinalysis and clinical chemistry systems and reagents for hospitals and laboratories worldwide. What are the underlying business or industry changes driving this perspective?
Nouveau récit • May 24

Aging Demographics And Global Expansion Will Drive Long Term Diagnostic Demand

Catalysts About Sysmex Sysmex is a global diagnostics company focused on hematology, hemostasis, urinalysis and clinical chemistry systems and reagents for hospitals and laboratories. What are the underlying business or industry changes driving this perspective?
Article d’analyse • May 21

Sysmex's (TSE:6869) Soft Earnings Are Actually Better Than They Appear

Soft earnings didn't appear to concern Sysmex Corporation's ( TSE:6869 ) shareholders over the last week. Our analysis...
Article d’analyse • May 17

Sysmex Corporation (TSE:6869) Annual Results: Here's What Analysts Are Forecasting For This Year

Last week saw the newest yearly earnings release from Sysmex Corporation ( TSE:6869 ), an important milestone in the...
Article d’analyse • Feb 15

Sysmex Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

There's been a notable change in appetite for Sysmex Corporation ( TSE:6869 ) shares in the week since its quarterly...
Article d’analyse • Feb 09

Sysmex (TSE:6869) Is Due To Pay A Dividend Of ¥19.00

Sysmex Corporation ( TSE:6869 ) has announced that it will pay a dividend of ¥19.00 per share on the 30th of June. This...
Article d’analyse • Feb 06

Estimating The Intrinsic Value Of Sysmex Corporation (TSE:6869)

Key Insights The projected fair value for Sysmex is JP¥1,737 based on 2 Stage Free Cash Flow to Equity With JP¥1,492...
Article d’analyse • Jan 05

Sysmex Corporation's (TSE:6869) Share Price Matching Investor Opinion

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 14x, you may consider Sysmex...
Article d’analyse • Dec 18

These 4 Measures Indicate That Sysmex (TSE:6869) Is Using Debt Reasonably Well

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse • Dec 03

Sysmex (TSE:6869) Will Pay A Dividend Of ¥19.00

Sysmex Corporation's ( TSE:6869 ) investors are due to receive a payment of ¥19.00 per share on 30th of June. This will...
Article d’analyse • Nov 09

Earnings Miss: Sysmex Corporation Missed EPS By 6.2% And Analysts Are Revising Their Forecasts

Last week, you might have seen that Sysmex Corporation ( TSE:6869 ) released its half-year result to the market. The...
Article d’analyse • Oct 28

Returns On Capital At Sysmex (TSE:6869) Have Stalled

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Article d’analyse • Sep 04

Sysmex's (TSE:6869) Dividend Will Be Increased To ¥19.00

Sysmex Corporation ( TSE:6869 ) has announced that it will be increasing its dividend from last year's comparable...
Article d’analyse • Aug 24

Sysmex Corporation's (TSE:6869) Earnings Haven't Escaped The Attention Of Investors

With a price-to-earnings (or "P/E") ratio of 26x Sysmex Corporation ( TSE:6869 ) may be sending very bearish signals at...

Prévisions de croissance des bénéfices et des revenus

TSE:6869 - Estimations futures des analystes et données financières antérieures (JPY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
3/31/2029601,70757,73045,73997,01014
3/31/2028570,33149,88639,18189,35215
3/31/2027542,52840,95336,02285,80014
6/30/2026524,94939,59551,01599,951N/A
3/31/2026500,00635,45722,87973,848N/A
12/31/2025502,94544,74827,42979,368N/A
9/30/2025498,69146,68623,89776,177N/A
6/30/2025502,42847,19127,92279,772N/A
3/31/2025508,64353,66938,28788,246N/A
12/31/2024501,85157,79036,79483,959N/A
9/30/2024491,29153,45532,05083,365N/A
6/30/2024478,10552,04920,18470,528N/A
3/31/2024461,51049,63913,71463,905N/A
12/31/2023438,28445,06317,88467,822N/A
9/30/2023429,17843,98124,43571,237N/A
6/30/2023419,82446,37532,65676,345N/A
3/31/2023410,50245,78426,33068,835N/A
12/31/2022403,62246,37710,93047,673N/A
9/30/2022389,04945,83913,27149,778N/A
6/30/2022370,44642,13014,59847,540N/A
3/31/2022363,78044,09326,70558,739N/A
12/31/2021352,12642,75538,11470,008N/A
9/30/2021341,74442,73245,44172,223N/A
6/30/2021323,92538,64836,70663,941N/A
3/31/2021305,07333,14233,02058,813N/A
12/31/2020295,66631,67532,52057,779N/A
9/30/2020291,07229,94324,74150,094N/A
6/30/2020293,95132,67327,96955,350N/A
3/31/2020301,98034,883N/A53,182N/A
12/31/2019303,29638,813N/A50,806N/A
9/30/2019300,30239,344N/A52,225N/A
6/30/2019296,08538,497N/A49,183N/A
3/31/2019293,50641,224N/A44,743N/A
12/31/2018287,75637,574N/A47,106N/A
9/30/2018287,02239,502N/A48,028N/A
6/30/2018286,17740,426N/A45,698N/A
3/31/2018281,93539,222N/A52,240N/A
12/31/2017271,65739,224N/A49,158N/A
9/30/2017262,20736,345N/A41,613N/A
6/30/2017252,45139,407N/A41,968N/A
3/31/2017249,89940,636N/A32,832N/A
12/31/2016248,26541,115N/A33,562N/A
9/30/2016250,18442,910N/A37,052N/A
6/30/2016254,68338,176N/A37,911N/A
3/31/2016253,15736,233N/A39,567N/A
12/31/2015251,20933,103N/A38,434N/A
9/30/2015244,02830,712N/A38,559N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 6869 ( 12.9% par an) est supérieure au taux d'épargne ( 0.9% ).

Bénéfices vs marché: Les bénéfices de 6869 ( 12.9% par an) devraient croître plus rapidement que le marché JP ( 8.8% par an).

Croissance élevée des bénéfices: Les bénéfices de 6869 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 6869 ( 5.1% par an) devrait croître plus lentement que le marché de JP ( 6.1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 6869 ( 5.1% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 6869 devrait être faible dans 3 ans ( 10.6 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/08/20 06:53
Cours de l'action en fin de journée2026/08/20 00:00
Les revenus2026/06/30
Revenus annuels2026/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Sysmex Corporation est couverte par 29 analystes. 15 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Masahiro NakanomyoBarclays
Kei TakeuchiBofA Global Research
Hidemaru YamaguchiCitigroup Inc